Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Saskatchewan

$27,000.00

Characterizing Clozapine use in Pediatric Psychiatry: A Retrospective Review of Clinical Practice

FY 2025-26

Summary
Children and adolescents with severe mental health conditions often face complex symptoms that do not respond to standard treatments. Clozapine is the most effective medication for treatment-resistant schizophrenia in adults, but it is rarely studied in younger patients and not officially approved for pediatric use. In Saskatchewan, clozapine use among pediatric patients has been noted, with anecdotal accounts suggesting use for non-psychotic indications such as aggression, mood instability, or behavioral dysregulation. This study will review medical charts from the Saskatoon and Prince Albert Child and Adolescent Psychiatry program to understand how clozapine is being used in real-world practice. It will describe who these children are, why they are prescribed clozapine, how it is dosed and monitored, and what outcomes or side effects occur before and after treatment. By examining these patterns, the research aims to ensure that children are receiving safe, appropriate, and effective care. The findings will help physicians, pharmacists, and families/caregivers make better-informed decisions about clozapine treatment in youth. Additionally, this work with provide insight for the Saskatchewan Health Authority and national policymakers, contributing to safer, more consistent, and evidence-based care for some of Canada’s most vulnerable youth.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572629
Name
Gessner Brooke K
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing Clozapine use in Pediatric Psychiatry: A Retrospective Review of Clinical Practice
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Atypical Antipsychotics; Child And Adolescent Mental Health; Clozapine; Neurodevelopment Disorders; Pediatric Psychiatry; Psychopharmacology; Treatment-Resistant Schizophrenia
Abstract
Children and adolescents with severe mental health conditions often face complex symptoms that do not respond to standard treatments. Clozapine is the most effective medication for treatment-resistant schizophrenia in adults, but it is rarely studied in younger patients and not officially approved for pediatric use. In Saskatchewan, clozapine use among pediatric patients has been noted, with anecdotal accounts suggesting use for non-psychotic indications such as aggression, mood instability, or behavioral dysregulation. This study will review medical charts from the Saskatoon and Prince Albert Child and Adolescent Psychiatry program to understand how clozapine is being used in real-world practice. It will describe who these children are, why they are prescribed clozapine, how it is dosed and monitored, and what outcomes or side effects occur before and after treatment. By examining these patterns, the research aims to ensure that children are receiving safe, appropriate, and effective care. The findings will help physicians, pharmacists, and families/caregivers make better-informed decisions about clozapine treatment in youth. Additionally, this work with provide insight for the Saskatchewan Health Authority and national policymakers, contributing to safer, more consistent, and evidence-based care for some of Canada’s most vulnerable youth.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gessner, Brooke K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~